Literature DB >> 19158340

The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration.

Dandan Zhong1, Jingfeng Zhang, Shuai Yang, Unice J K Soh, Jan Paul Buschdorf, Yi Ting Zhou, Daiwen Yang, Boon Chuan Low.   

Abstract

Deleted in liver cancer 1 (DLC1) is a multi-modular Rho-GTPase-activating protein (RhoGAP) and a tumor suppressor. Besides its RhoGAP domain, functions of other domains in DLC1 remain largely unknown. By protein precipitation and mass spectrometry, we identified eukaryotic elongation factor 1A1 (EF1A1) as a novel partner for the sterile alpha motif (SAM) domain of DLC1 but not the SAM domain of DLC2. The solution structure of DLC1 SAM revealed a new monomeric fold with four parallel helices, similar to that of DLC2 SAM but distinct from other SAM domains. Mutating F38, L39 and F40 within a hydrophobic patch retained its overall structure but abolished its interaction with EF1A1 with F38 and L39 forming an indispensable interacting motif. DLC1 SAM did not localize to and was not required for DLC1 to suppress the turnover of focal adhesions. Instead, DLC1 SAM facilitated EF1A1 distribution to the membrane periphery and ruffles upon growth factor stimulation. Compared with wild-type DLC1, the non-interactive DLC1 mutant is less potent in suppressing cell migration, whereas overexpression of the DLC1 SAM domain alone, but not the non-interactive mutant SAM or DLC2 SAM, greatly enhanced cell migration. This finding reveals a novel contribution of the SAM-EF1A1 interaction as a potentially important GAP-independent modulation of cell migration by DLC1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158340     DOI: 10.1242/jcs.027482

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  26 in total

1.  DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.

Authors:  Xuyu Yang; Nicholas C Popescu; Drazen B Zimonjic
Journal:  Cancer Res       Date:  2011-03-03       Impact factor: 12.701

2.  DLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity.

Authors:  Veenu Tripathi; Nicholas C Popescu; Drazen B Zimonjic
Journal:  Mol Cell Biol       Date:  2012-04-02       Impact factor: 4.272

Review 3.  StarD13: a potential star target for tumor therapeutics.

Authors:  Leila Jaafar; Zeinab Chamseddine; Mirvat El-Sibai
Journal:  Hum Cell       Date:  2020-04-09       Impact factor: 4.174

4.  Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells.

Authors:  Yi-Ping Shih; Yoshikazu Takada; Su Hao Lo
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

5.  Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.

Authors:  Archna Ravi; Shelly Kaushik; Aarthi Ravichandran; Catherine Qiurong Pan; Boon Chuan Low
Journal:  J Biol Chem       Date:  2014-12-18       Impact factor: 5.157

6.  DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.

Authors:  Rakesh Joshi; Lyugao Qin; Xuan Cao; Shanshan Zhong; Courtney Voss; Weiping Min; Shawn S C Li
Journal:  J Biol Chem       Date:  2019-12-05       Impact factor: 5.157

7.  Identification and characterization of Dlc1 isoforms in the mouse and study of the biological function of a single gene trapped isoform.

Authors:  Mohammad G Sabbir; Nichola Wigle; Shauna Loewen; Yuan Gu; Cordula Buse; Geoffrey G Hicks; Michael R A Mowat
Journal:  BMC Biol       Date:  2010-03-03       Impact factor: 7.431

8.  DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain.

Authors:  Patrik Erlmann; Simone Schmid; Florian A Horenkamp; Matthias Geyer; Thomas G Pomorski; Monilola A Olayioye
Journal:  Mol Biol Cell       Date:  2009-08-26       Impact factor: 4.138

9.  DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis.

Authors:  Yufeng Wang; Rong Lei; Xueqian Zhuang; Ning Zhang; Hong Pan; Gang Li; Jing Hu; Xiaoqi Pan; Qian Tao; Da Fu; Jianru Xiao; Y Eugene Chin; Yibin Kang; Qifeng Yang; Guohong Hu
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

10.  Deleted in liver cancer protein family in human malignancies (Review).

Authors:  D Lukasik; E Wilczek; A Wasiutynski; B Gornicka
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.